Gastromedisinsk forskningsgruppe
Fra venstre i bildet! Frode Lerang (Overlege dr.med), Magne Henriksen (Overlege, PhD), Henrik Wåhlberg (Lis-lege og stipendiat), Jan Novotny (Overlege), Nina Bråthen (studiesykepleier), Erik Christensen (Overlege), Taran Søberg (Overlege), Per Sandvei (Avdelingssjef, overlege), Lars-Petter Jelsness-Jørgensen (Forskningsgruppeleder, Professor PhD)
Gruppen jobber for å styrke forskning på ulike fordøyelsesrelaterte plager og sykdommer. Primærfokus er inflammatorisk tarmsykdom (IBD), gastrointestinale blødninger, pasientrapporterte utfallsmål
| Navn | Arbeidssted | Jobbtittel | Tittel |
|---|---|---|---|
| Lars-Petter Jelsness-Jørgensen | Sykehuset Østfold – Høgskolen i Østfold | Seniorforsker - sykepleier | Leder av gruppen - Professor |
| Frode Lerang | Sykehuset Østfold | Overlege | Akademisk stilling |
| Magne Henriksen | Sykehuset Østfold | Overlege | Akademisk stilling |
| Per Sandvei | Sykehuset Østfold | Avdelingssjef | Akademisk stiling |
| Rogelio Barreto Rios | Sykehuset Østfold | Overlege | PhD |
| Taran Søberg | Sykehuset Østfold | Overlege | |
| Kristina Aas Holten | Sykehuset Østfold | LIS | PhD stipendiat |
| Henrik Wåhlberg | Sykehuset Østfold | Overlege | PhD |
| Kathrine Romstad | Sykehuset Østfold | Kst. overlege | PhD stipendiat |
| Svein Oscar Frigstad | Sykehuset Asker og Bærum – Sykehuset Østfold | Seksjonsoverlege | PhD stipendiat |
- Kathrine Romstad: Blue-studien (UiO): Hovedfokus er blødende ulcussykdom
- Svein Oskar Frigstad: Vitality studien: Vitamin D, prevalens og assosiasjoner til pasientrapporterte utfallsmål (UiO)
- IBSEN III: Prospektiv, multisenter studie som kartlegger alle nydiagnostiserte tilfeller av inflammatorisk tarmsykdom. Studien har en bredt anlagt datainnsamling som inkluderer genetiske markører, kliniske data, endoskopi, ernæring, radiologi, mikrobiota, symptomer/livskvalitet og data relatert til sykefravær og uføretrygd.
- Vitality: Multisenterstudie som kartlegger forekomst av vitamin d mangel blant pasienter med IBD, samt ulike pasientrapporterte endepunkter og helsetjenestekvalitet.
- BioSTOP: Multisenterstudie som kartlegger langtidseffekter knyttet til å stoppe eller kontinuere biologisk behandling hos pasienter med ulcerøs kolitt i vedvarende remisjon.
- HpEUreg: Internasjonal studie og kartlegging av Helicobacter Pylori
- Blue-studien: Kartlegging av blødende ulcusssykdom
- Epos: Europeisk Polypp Observasjonsstudie. Kartlegging av oppfølginsprosedyrer/intervaller etter fjerning av polypper.
1. Jørgensen KK et. al. Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching
from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
BioDrugs. 2020 Oct;34(5):681-694. doi: 10.1007/s40259-020-00438-7.
2. Klepp P et al. Risk of colorectal cancer in a population-based study 20 years after diagnosis of
ulcerative colitis: results from the IBSEN study. BMJ Open Gastroenterol. 2020 Mar 26;7(1):e000361.
doi: 10.1136/bmjgast-2019-000361. eCollection 2020.
3. Henriksen M, Høivik ML, Jelsness-Jørgensen LP, Moum B; IBSEN Study Group. Irritable Bowel-like
Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation:
Results From a Population-based Study [the IBSEN Study]. J Crohns Colitis. 2018 Mar 28;12(4):389-
393. doi: 10.1093/ecco-jcc/jjx152.
4. Ossum AM et al. Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term
Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study. J Crohns Colitis.
2018 Jan 5;12(1):96-104. doi: 10.1093/ecco-jcc/jjx126.
5. Lunder AK et. al. Bowel Damage in Patients With Long-term Crohn's Disease, Assessed by Magnetic
Resonance Enterography and the Lémann Index. Clin Gastroenterol Hepatol. 2018 Jan;16(1):75-82.e5.
doi: 10.1016/j.cgh.2017.06.053. Epub 2017 Jul 8.
6. Jørgensen KK et al; NOR-SWITCH study group. Switching from originator infliximab to biosimilar CTP13
compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week,
randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304-2316. doi:
10.1016/S0140-6736(17)30068-5. Epub 2017 May 11.
7. Hovde Ø, Høivik ML, Henriksen M, Solberg IC, Småstuen MC, Moum BA. Malignancies in Patients with
Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study. J Crohns Colitis.
2017 May 1;11(5):571-577. doi: 10.1093/ecco-jcc/jjw193.
8. Huppertz-Hauss G et al. Fatigue in a population-based cohort of patients with inflammatory bowel
disease 20 years after diagnosis: The IBSEN study. Scand J Gastroenterol. 2017 Mar;52(3):351-358.
doi: 10.1080/00365521.2016.1256425. Epub 2016 Nov 17.
9. Lunder AK et al. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance
Cholangiography in Patients With Long-term Inflammatory Bowel Disease. Gastroenterology. 2016
Oct;151(4):660-669.e4. doi: 10.1053/j.gastro.2016.06.021. Epub 2016 Jun 21.
10. Nyssen OP et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and
trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.
Gut. 2020 Sep 21:gutjnl-2020-321372. doi: 10.1136/gutjnl-2020-321372. Online ahead of print.
11. Romstad KK, Detlie TE, Søberg T, Ricanek P, Jahnsen ME, Lerang F, Jahnsen J. Gastrointestinal
bleeding due to peptic ulcers and erosions - a prospective observational study (BLUE study). Scand J
Gastroenterol. 2020 Oct;55(10):1139-1145. doi: 10.1080/00365521.2020.1819405. Epub 2020 Sep 15.
12. Hoff et al. Patient-reported adverse events after colonoscopy in Norway. Endoscopy. 2017
Aug;49(8):745-753. doi: 10.1055/s-0043-105265. Epub 2017 Apr 26.
13. Farrell D et al. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev.
2020 Apr 16;4(4):CD012005. doi: 10.1002/14651858.CD012005.pub2.
14. Opheim R et al. Self-esteem in patients with inflammatory bowel disease. Qual Life Res. 2020
Jul;29(7):1839-1846. doi: 10.1007/s11136-020-02467-9. Epub 2020 Mar 6.
15. Frigstad SO et al. Pain Severity and Vitamin D Deficiency in IBD Patients. Nutrients. 2019 Dec
20;12(1):26. doi: 10.3390/nu12010026.
16. Jelsness-Jørgensen LP, Bernklev T, Lundin KEA. Fatigue as an Extra-Intestinal Manifestation of Celiac
Disease: A Systematic Review. Nutrients. 2018 Nov 3;10(11):1652. doi: 10.3390/nu10111652.
17. Frigstad SO et al. Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease
patients. World J Gastroenterol. 2018 Aug 7;24(29):3293-3301. doi: 10.3748/wjg.v24.i29.3293.
18. Jelsness-Jørgensen LP et al. Pain may be an important factor to consider in inflammatory bowel
disease patients troubled by fatigue. United European Gastroenterol J. 2017 Aug;5(5):687-693. doi:
10.1177/2050640616674654. Epub
19. Dibley L et al. Identification of Research Priorities for Inflammatory Bowel Disease Nursing in Europe:
a Nurses-European Crohn's and Colitis Organisation Delphi Survey. J Crohns Colitis. 2017 Mar
1;11(3):353-359. doi: 10.1093/ecco-jcc/jjw164.
Last updated 11/22/2022